Moderna CEO Stéphane Bancel (AP Images)
August 22, 2020 09:47 AM EDTUpdated August 24, 06:38 AM
Bioregnum
Coronavirus
Opinion

The lead­ers in the race to de­vel­op a Covid-19 vac­cine say they could have piv­otal da­ta in Oc­to­ber — but Trump claims FDA is slow­ing re­cruit­ment

Late Fri­day night Mod­er­na tweet­ed that their Phase III study had come close to the halfway mark in re­cruit­ing the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

A service from the Financial Times